• Publications
  • Influence
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurologicalExpand
  • 2,097
  • 63
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectivelyExpand
  • 1,265
  • 49
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
BACKGROUND An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonalExpand
  • 615
  • 49
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
We report the results of a meta-analysis of genome-wide association scans for multiple sclerosis (MS) susceptibility that includes 2,624 subjects with MS and 7,220 control subjects. Replication in anExpand
  • 699
  • 35
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis
BACKGROUND B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS In two identical phase 3 trials,Expand
  • 545
  • 35
Methods for high-density admixture mapping of disease genes.
Admixture mapping (also known as "mapping by admixture linkage disequilibrium," or MALD) has been proposed as an efficient approach to localizing disease-causing variants that differ in frequencyExpand
  • 454
  • 34
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
BACKGROUND B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibodyExpand
  • 500
  • 31
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
The autoimmune model of multiple sclerosis (MS) pathogenesis provided for many years a useful but incomplete conceptual framework for understanding the complex array of factors that lead to the lossExpand
  • 657
  • 31
Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis
Multiple sclerosis is a demyelinating neurodegenerative disease with a strong genetic component. Previous genetic risk studies have failed to identify consistently linked regions or genes outside ofExpand
  • 578
  • 28
Identification of autoantibodies associated with myelin damage in multiple sclerosis
The molecular mechanisms underlying myelin sheath destruction in multiple sclerosis lesions remain unresolved. With immunogold–labeled peptides of myelin antigens and high–resolution microscopy,Expand
  • 848
  • 27